EUVIMEDOpdag EUVIMED
Open access

Cost-Effectiveness of AI-Powered Decentralized Production for Advanced Therapies in the Hospital–Generated Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma From a German Hospital Perspective: Early Health Technology Assessment Study

Iris W A Boot iD, Anna Louisa Weltin iD, Ysanne de Graaf iD, Hubertus J M Vrijhoef iD

JMIR Cancer · 2026

DOI: 10.2196/92253 ↗

At a glance

Journal article in JMIR Cancer, 2026. Written by Iris W A Boot and 3 co-authors. Institution: Panaxea, 's-Hertogenbosch, The Netherlands. Major MEDLINE topics: Multiple Myeloma, Technology Assessment, Biomedical, Immunotherapy, Adoptive, Receptors, Chimeric Antigen. 60 references. The full text is freely available in PubMed Central.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Although effective, current chimeric antigen receptor T-cell (CAR-T) production methods—centralized, manual, and complex—are cost-intensive, time-consuming, and prone to variability. AIDPATH (AI-Powered Decentralized Production for Advanced Therapies in the Hospital) proposes a decentralized, automated alternative that integrates patient-specific data; optimizes resource use; and potentially improves cell viability, manufacturing efficiency, and patient outcomes.

Objective

The aim of this study was to compare CAR-T therapy produced by the AIDPATH platform to both ciltacabtagene autoleucel (cilta-cel) and standard of care (SoC) for patients with triple-class refractory multiple myeloma (MM) over a 40-year time horizon from the hospital perspective in Germany.

Methods

A partitioned survival model reflecting 3 health states (progression-free disease, progressed disease, and death) was used. The analysis used clinical trial data for cilta-cel, real-world data for SoC, and estimated parameters for AIDPATH due to the developmental status of the platform. The primary outcome was the incremental cost-effectiveness ratio; secondary outcomes included sensitivity and scenario analyses.

Results

On the basis of the model used in this analysis, AIDPATH was dominant compared to both cilta-cel and SoC. Most costs for CAR-T therapies were driven by acquisition and adverse events. Sensitivity analyses showed that the results were most influenced by discount rates and assumptions about progression-free survival. Scenario analyses, including reduced adverse events and shorter vein-to-vein times for AIDPATH, further supported its cost-effectiveness.

Conclusions

This is the first study to assess the cost-effectiveness of a CAR-T product generated with AI support in Germany from the hospital perspective. AIDPATH was found to be a cost-effective alternative to both cilta-cel and SoC, making it a promising option for future implementation. Although further data are needed, this study provides valuable guidance for health care stakeholders, reimbursement discussions, and future research.

Subjects

MeSH terms (MEDLINE)

Multiple MyelomaTechnology Assessment, BiomedicalImmunotherapy, AdoptiveReceptors, Chimeric AntigenArtificial IntelligenceHumansCost-Benefit AnalysisCost-Effectiveness AnalysisGermany

Author keywords

AI manufacturingCAR-T therapyartificial intelligence manufacturingautomated decentralized manufacturingchimeric antigen receptor T-cell therapycost-effectiveness analysisearly HTAearly health technology assessmenthealth economic modeling

Substances

Receptors, Chimeric Antigen

Authors and institutions

  • Panaxea, 's-Hertogenbosch, The Netherlands.
  • Department Bio-adaptive Production, Fraunhofer Institute for Production Technology IPT, Aachen, North Rhine-Westphalia, Germany.
  • Faculty of Health, Medicine and Life Sciences, Maastricht University, Maatricht, Limburg, The Netherlands.

ORCID profiles: Iris W A Boot, Anna Louisa Weltin, Ysanne de Graaf, Hubertus J M Vrijhoef

Cite

APA

Boot, I. W. A., Weltin, A. L., de Graaf, Y., & Vrijhoef, H. J. M. (2026). Cost-Effectiveness of AI-Powered Decentralized Production for Advanced Therapies in the Hospital–Generated Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma From a German Hospital Perspective: Early Health Technology Assessment Study. JMIR Cancer. https://doi.org/10.2196/92253

Vancouver

Boot IWA, Weltin AL, de Graaf Y, Vrijhoef HJM. Cost-Effectiveness of AI-Powered Decentralized Production for Advanced Therapies in the Hospital–Generated Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma From a German Hospital Perspective: Early Health Technology Assessment Study. JMIR Cancer. 2026. doi:10.2196/92253

BibTeX
@article{Boot2026,
  author = {Boot, Iris W A and Weltin, Anna Louisa and de Graaf, Ysanne and Vrijhoef, Hubertus J M},
  title = {Cost-Effectiveness of AI-Powered Decentralized Production for Advanced Therapies in the Hospital–Generated Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma From a German Hospital Perspective: Early Health Technology Assessment Study},
  journal = {JMIR Cancer},
  year = {2026},
  doi = {10.2196/92253}
}
Start for free →